Endosheath超细经鼻内镜在胃食管反流症状患者中筛查巴雷特食管具成本效益
研究用马尔可夫模型模拟50岁白人男性胃食管反流患者终身筛查,比较Endosheath超细经鼻内镜、标准内镜与不筛查的成本效用。超细经鼻内镜较不筛查增加0.039个质量调整生命年,增量成本效用比每质量调整生命年29446美元;标准内镜增加0.034个质量调整生命年,增量成本效用比47563美元。作者认为在50000美元支付意愿阈值下两者均具成本效益。
要点
- 超细经鼻内镜筛查较不筛查每质量调整生命年增量成本效用比为29446美元。
- 标准内镜筛查较不筛查每质量调整生命年增量成本效用比为47563美元。
- 在50000美元支付意愿阈值下两种内镜筛查策略均具成本效益。
核心结论
- 在50岁有胃食管反流症状的白人男性筛查队列中,超细经鼻内镜与标准内镜在50000美元支付意愿阈值下似乎均具成本效益。
研究设计与样本
- 采用马尔可夫模型模拟50岁有胃食管反流症状的白人男性终身筛查,从医疗付费方角度使用直接成本。
- 比较Endosheath超细经鼻内镜筛查、标准内镜筛查与不筛查三种策略。
- 模型输入变量基于文献及近期超细经鼻内镜筛查巴雷特食管的数据。
- 主要结局为成本、质量调整生命年及增量成本效用比,并对巴雷特食管患病率等因素行敏感性分析。
主要发现
- 超细经鼻内镜、标准内镜与不筛查的成本分别估计为2495美元、2957美元和1436美元。
- 与不筛查相比,标准内镜筛查增加0.034个质量调整生命年(95%置信区间0.015至0.056),增量成本效用比为47563美元(95%置信区间31036至82970)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Barrett's esophagus (BE) screening is currently not considered to be cost effective in the general population but may be effective in high-risk subgroups, such as 50-year-old white men with chronic reflux disease (GERD). A new modality for screening is unsedated transnasal endoscopy using endosheath technology (uTNE), which has been shown to be safe and effective in clinical practice. In this study, we determined the cost-utility of uTNE in a high-risk subgroup compared with no screening or screening with standard endoscopy. METHODS: A Markov model was used to simulate screening of 50-year-old white men with symptoms of GERD with either uTNE or standard endoscopy compared with no screening, over a lifetime horizon. Input variables were based on the literature and recent data on uTNE screening for BE. The study was designed from a healthcare payer perspective by using direct costs. Primary outcome measures were costs, quality-adjusted life years (QALYs), and the incremental cost-utility ratio (ICUR) of uTNE and standard endoscopy compared with no screening. Sensitivity analysis was performed for several factors, such as prevalence of BE. RESULTS: Costs of uTNE, standard endoscopy, and no screening were estimated at, $2495, $2957, and $1436, respectively. Compared with no screening, uTNE screening resulted in an overall QALY increase of 0.039 (95% percentile 0.018; 0.063) and an ICUR of $29,446 per QALY gained (95% confidence interval [CI], 18.516-53.091), whereas standard endoscopy compared with no screening resulted in a QALY increase of 0.034 (95% CI, 0.015-0.056) and an ICUR of $47,563 (95% CI, 31,036-82,970). CONCLUSION: Both uTNE and standard endoscopy seem to be cost-effective screening methods in a screening cohort of 50-year-old white men with GERD at a willingness-to-pay cutoff of $50,000.
引用
- Honing J, Kievit W, Bookelaar J, et al. Endosheath ultrathin transnasal endoscopy is a cost-effective method for screening for Barrett's esophagus in patients with GERD symptoms. Gastrointest Endosc. 2018. PMID: 30385112. doi:10.1016/j.gie.2018.10.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。